{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Washington+D.C.&state=District+of+Columbia", "query": { "state": "District of Columbia", "city": "Washington D.C." }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 181, "total_pages": 19, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Washington+D.C.&state=District+of+Columbia&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-07T14:52:13.852Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00954174", "title": "Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Mixed Mesodermal (Mullerian) Tumor", "Ovarian Carcinosarcoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma", "Stage I Ovarian Cancer AJCC v6 and v7", "Stage IA Fallopian Tube Cancer AJCC v6 and v7", "Stage IA Ovarian Cancer AJCC v6 and v7", "Stage IA Uterine Sarcoma AJCC v7", "Stage IB Fallopian Tube Cancer AJCC v6 and v7", "Stage IB Ovarian Cancer AJCC v6 and v7", "Stage IB Uterine Sarcoma AJCC v7", "Stage IC Fallopian Tube Cancer AJCC v6 and v7", "Stage IC Ovarian Cancer AJCC v6 and v7", "Stage IC Uterine Sarcoma AJCC v7", "Stage II Ovarian Cancer AJCC v6 and v7", "Stage IIA Fallopian Tube Cancer AJCC v6 and v7", "Stage IIA Ovarian Cancer AJCC V6 and v7", "Stage IIA Uterine Sarcoma AJCC v7", "Stage IIB Fallopian Tube Cancer AJCC v6 and v7", "Stage IIB Ovarian Cancer AJCC v6 and v7", "Stage IIB Uterine Sarcoma AJCC v7", "Stage IIC Fallopian Tube Cancer AJCC v6 and v7", "Stage IIC Ovarian Cancer AJCC v6 and v7", "Stage IIIA Fallopian Tube Cancer AJCC v7", "Stage IIIA Ovarian Cancer AJCC v6 and v7", "Stage IIIA Primary Peritoneal Cancer AJCC v7", "Stage IIIA Uterine Sarcoma AJCC v7", "Stage IIIB Fallopian Tube Cancer AJCC v7", "Stage IIIB Ovarian Cancer AJCC v6 and v7", "Stage IIIB Primary Peritoneal Cancer AJCC v7", "Stage IIIB Uterine Sarcoma AJCC v7", "Stage IIIC Fallopian Tube Cancer AJCC v7", "Stage IIIC Ovarian Cancer AJCC v6 and v7", "Stage IIIC Primary Peritoneal Cancer AJCC v7", "Stage IIIC Uterine Sarcoma AJCC v7", "Stage IV Fallopian Tube Cancer AJCC v6 and v7", "Stage IV Ovarian Cancer AJCC v6 and v7", "Stage IV Primary Peritoneal Cancer AJCC v7", "Stage IVA Uterine Sarcoma AJCC v7", "Stage IVB Uterine Sarcoma AJCC v7", "Uterine Carcinosarcoma" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "GOG Foundation", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 637, "start_date": "2009-08-17", "completion_date": null, "has_results": true, "last_update_posted_date": "2021-09-30", "last_synced_at": "2026-06-07T14:52:13.852Z", "location_count": 532, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 346 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00954174" }, { "nct_id": "NCT04566328", "title": "Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Plasma Cell Myeloma", "RISS Stage I Plasma Cell Myeloma", "RISS Stage II Plasma Cell Myeloma" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Daratumumab and Hyaluronidase-fihj", "type": "BIOLOGICAL" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "ECOG-ACRIN Cancer Research Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1450, "start_date": "2021-02-24", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-06-07T14:52:13.852Z", "location_count": 642, "location_summary": "Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 457 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04566328" }, { "nct_id": "NCT00004978", "title": "An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Recombinant interleukin-2 (rIL-2)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4150, "start_date": "2000-03", "completion_date": "2008-11", "has_results": true, "last_update_posted_date": "2021-11-05", "last_synced_at": "2026-06-07T14:52:13.852Z", "location_count": 78, "location_summary": "Los Angeles, California • Mill Valley, California • Oakland, California + 33 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Mill Valley", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004978" }, { "nct_id": "NCT00625898", "title": "BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Epirubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NSABP Foundation Inc", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 3509, "start_date": "2008-04", "completion_date": "2014-07", "has_results": false, "last_update_posted_date": "2020-09-10", "last_synced_at": "2026-06-07T14:52:13.852Z", "location_count": 393, "location_summary": "Birmingham, Alabama • Decatur, Alabama • Huntsville, Alabama + 272 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Decatur", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Flagstaff", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00625898" }, { "nct_id": "NCT04134260", "title": "Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Adenocarcinoma", "Stage I Prostate Cancer AJCC v8", "Stage II Prostate Cancer AJCC v8", "Stage III Prostate Cancer AJCC v8", "Stage IVA Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Apalutamide", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Hormone Therapy", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER", "RADIATION" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 586, "start_date": "2020-04-16", "completion_date": "2026-11-01", "has_results": false, "last_update_posted_date": "2026-05-07", "last_synced_at": "2026-06-07T14:52:13.852Z", "location_count": 345, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 256 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Baldwin Park", "state": "California" }, { "city": "Bellflower", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04134260" }, { "nct_id": "NCT00262847", "title": "Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Fallopian Tube Clear Cell Adenocarcinoma", "Fallopian Tube Endometrioid Adenocarcinoma", "Fallopian Tube Mucinous Adenocarcinoma", "Fallopian Tube Serous Adenocarcinoma", "Fallopian Tube Transitional Cell Carcinoma", "Malignant Ovarian Mixed Epithelial Tumor", "Ovarian Brenner Tumor", "Ovarian Clear Cell Adenocarcinoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian Mucinous Adenocarcinoma", "Ovarian Serous Adenocarcinoma", "Ovarian Transitional Cell Carcinoma", "Primary Peritoneal Serous Adenocarcinoma", "Stage IIIA Fallopian Tube Cancer", "Stage IIIA Ovarian Cancer", "Stage IIIA Primary Peritoneal Cancer", "Stage IIIB Fallopian Tube Cancer", "Stage IIIB Ovarian Cancer", "Stage IIIB Primary Peritoneal Cancer", "Stage IIIC Fallopian Tube Cancer", "Stage IIIC Ovarian Cancer", "Stage IIIC Primary Peritoneal Cancer", "Stage IV Fallopian Tube Cancer", "Stage IV Ovarian Cancer", "Stage IV Primary Peritoneal Cancer", "Undifferentiated Fallopian Tube Carcinoma", "Undifferentiated Ovarian Carcinoma" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 1873, "start_date": "2005-09", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2019-07-23", "last_synced_at": "2026-06-07T14:52:13.852Z", "location_count": 614, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 395 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00262847" }, { "nct_id": "NCT00807768", "title": "Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Endometrial Clear Cell Adenocarcinoma", "Endometrial Serous Adenocarcinoma", "Fatigue", "Neurotoxicity Syndrome", "Obesity", "Stage I Uterine Corpus Cancer AJCC v7", "Stage II Uterine Corpus Cancer AJCC v7" ], "interventions": [ { "name": "3-Dimensional Conformal Radiation Therapy", "type": "RADIATION" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Internal Radiation Therapy", "type": "RADIATION" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "RADIATION", "DRUG", "OTHER" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 601, "start_date": "2009-03-23", "completion_date": null, "has_results": true, "last_update_posted_date": "2019-03-20", "last_synced_at": "2026-06-07T14:52:13.852Z", "location_count": 533, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 352 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00807768" }, { "nct_id": "NCT00048958", "title": "Cytogenetic Studies in Acute Leukemia and Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Acute Leukemia", "Acute Lymphoblastic Leukemia", "Myelodysplastic Syndrome", "Multiple Myeloma" ], "interventions": [ { "name": "cytogenetic analysis", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9000, "start_date": "1984-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2024-07-31", "last_synced_at": "2026-06-07T14:52:13.852Z", "location_count": 137, "location_summary": "La Jolla, California • Mountain View, California • San Diego, California + 89 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Mountain View", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00048958" }, { "nct_id": "NCT04544449", "title": "A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Sclerosis, Primary Progressive" ], "interventions": [ { "name": "Fenebrutinib", "type": "DRUG" }, { "name": "Ocrelizumab", "type": "DRUG" }, { "name": "Placebo matched to ocrelizumab", "type": "DRUG" }, { "name": "Placebo matched to fenebrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 985, "start_date": "2020-10-26", "completion_date": "2027-07-21", "has_results": false, "last_update_posted_date": "2026-03-27", "last_synced_at": "2026-06-07T14:52:13.852Z", "location_count": 43, "location_summary": "Homewood, Alabama • Berkeley, California • Fullerton, California + 40 more", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Berkeley", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Sunnyvale", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04544449" }, { "nct_id": "NCT00013897", "title": "A Comparison of BMS-232632 With Efavirenz, Each in Combination With Zidovudine-Lamivudine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Atazanavir", "type": "DRUG" }, { "name": "Lamivudine/Zidovudine", "type": "DRUG" }, { "name": "Efavirenz", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": null, "start_date": "2001-02", "completion_date": "2003-04", "has_results": false, "last_update_posted_date": "2011-05-04", "last_synced_at": "2026-06-07T14:52:13.852Z", "location_count": 28, "location_summary": "Phoenix, Arizona • Los Angeles, California • San Francisco, California + 24 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00013897" } ] }